NIH recommends outpatient use of Regeneron's COVID-19 antibody cocktail

By The Science Advisory Board staff writers

April 9, 2021 -- Regeneron Pharmaceuticals said the U.S. National Institutes of Health (NIH) strongly recommends its Regen-CoV (casirivimab with imdevimab) as an outpatient treatment for COVID-19 patients at high risk of clinical progression.

In addition, some NIH panel members recommended the drug for areas with variants of the virus, as the monoclonal antibody treatment retains potency in vitro.

The newly updated treatment guidelines are based in part on clinical data involving more than 4,500 outpatients showing that Regen-CoV significantly reduced the risk of hospitalization or death by 70% versus placebo. The NIH's recommendation means Regen-CoV is one step closer to being made available for all applicable patients in the U.S., Regeneron said.

Clinical pipeline promises effective 2nd-generation COVID-19 vaccines
Despite the small number of COVID-19 vaccines that have been granted emergency use authorizations by the U.S. Food and Drug Administration to date, many...
NORD announces 2021 Rare Impact Award honorees
The National Organization for Rare Disorders (NORD) announced the honorees for the 2021 Rare Impact Awards.
Regeneron publishes data supporting Ab cocktail as passive COVID-19 vaccine
Regeneron said that interim data from its ongoing phase III clinical trial supports the use of its Regen-CoV antibody (Ab) cocktail as a passive vaccine...
Regulatory Roundup: Designations come through before year's end
This week's Regulatory Roundup covers activities from November 30 to December 4 and is filled with breakthrough, orphan, and rare disease designations...
FDA issues EUA for Regeneron's COVID-19 mAb cocktail
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) on November 21 for the casirivimab and imdevimab monoclonal antibody...

Copyright © 2021 scienceboard.net


Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter